Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a year-on-year increase of 15%[1]. - The net profit for the first half of 2022 was RMB 300 million, up 20% compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was ¥714,867,789.45, representing a year-on-year increase of 52.35% compared to ¥469,238,549.07 in the same period last year[15]. - The net profit attributable to shareholders for the same period was ¥133,654,117.58, reflecting an 85.36% increase from ¥72,104,655.39 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was ¥150,937,683.00, which is a 65.21% increase compared to ¥91,358,617.39 in the prior year[15]. - The basic earnings per share rose to ¥0.33, an increase of 83.33% from ¥0.18 in the previous year[16]. - The weighted average return on equity increased to 10.94%, up by 3.96 percentage points from 6.98% in the same period last year[16]. - The company has set a performance guidance for the full year, projecting a revenue target of RMB 2.5 billion, which would represent a 20% increase year-on-year[1]. Research and Development - Research and development expenses increased by 25% to RMB 150 million, focusing on innovative drug development[1]. - The company is focused on the research and development of recombinant proteins and long-acting modified drugs, particularly in the field of immune-related cytokine drugs, aiming to become a leader in systemic immune solutions for major diseases like viral hepatitis and malignant tumors[19]. - The company has established a complete R&D system covering drug technology development, quality control, preclinical and clinical research, and industrialization, enhancing its core competitiveness[22]. - The company reported a total R&D investment of ¥85,312,879.65, an increase of 23.12% compared to ¥69,294,111.95 in the same period last year[29]. - The company is conducting clinical research for multiple new drugs, including YPEG-GH and YPEG-EPO, with significant investments allocated for their development[32]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a revenue growth of 30% in that region by the end of 2022[1]. - The company plans to launch two new products in Q3 2022, aiming to capture an additional 5% market share[1]. - The company has completed a strategic acquisition of a smaller competitor for 500 million, expected to enhance its market position and capabilities[76]. - Market expansion plans include entering three new international markets by the end of the fiscal year, which is expected to increase market share by 15%[74]. Risk Management - The company has identified potential risks related to regulatory changes and supply chain disruptions, with mitigation strategies outlined in the report[1]. - The company faces risks related to drug bidding failures and price declines, which could impact sales revenue and net profit[43]. - The company is actively monitoring industry policy changes to mitigate risks and enhance its competitive edge[44]. Environmental and Social Responsibility - The company has maintained its ISO14001:2015 environmental management system certification, ensuring compliance with environmental protection laws and regulations[62]. - The company is actively promoting energy-saving and emission reduction management, planning to utilize idle rooftop space for photovoltaic power generation and construct two advanced dynamic ice storage cooling systems[63]. - The company emphasizes social responsibility, balancing economic and social benefits while actively participating in public welfare projects[64]. Shareholder and Governance Commitments - The actual controller and shareholders have committed to a 36-month lock-up period for shares post-IPO, ensuring stability in company operations[66]. - The company has established strict guidelines for share reduction, limiting the total number of shares sold by insiders within specified periods[67]. - The company commits to not transferring benefits to other entities or individuals under unfair conditions, ensuring the protection of company interests[88]. - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board, with multiple operational centers[150]. Financial Position and Assets - The total assets at the end of the reporting period were ¥1,534,305,058.10, a 7.73% increase from ¥1,424,174,930.07 at the end of the previous year[15]. - The total current assets amounted to CNY 822,356,286.60, compared to CNY 796,982,805.73, representing a growth of about 3.2%[125]. - Cash and cash equivalents amounted to RMB 403,796,509.40, up from RMB 285,415,325.22, indicating a significant increase of about 41.5%[121]. - The company's inventory reached RMB 123,631,378.29, compared to RMB 116,490,538.91 at the start of the period, representing an increase of approximately 6.3%[121]. Compliance and Reporting - The company adheres to the accounting standards for enterprises, ensuring that financial reports accurately reflect its financial position and performance[155]. - The financial statements are prepared based on the assumption of going concern, with no identified issues affecting the company's ability to continue operations[153]. - The company confirmed that there are no false records, misleading statements, or significant omissions in the prospectus for its initial public offering on the Sci-Tech Innovation Board[90].

Financial Performance - The company's operating revenue for Q1 2022 was ¥345,009,951.29, representing a year-on-year increase of 60.16%[4] - The net profit attributable to shareholders was ¥57,452,423.77, reflecting a growth of 67.90% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥75,548,263.15, which is an increase of 92.45% year-on-year[4] - Basic earnings per share were ¥0.14, up 75.00% compared to the same quarter last year[4] - Total operating revenue for Q1 2022 reached ¥345,009,951.29, a significant increase of 60.1% compared to ¥215,410,044.58 in Q1 2021[16] - Net profit for Q1 2022 was ¥57,452,423.77, representing a 67.9% increase from ¥34,217,953.38 in Q1 2021[17] - The total equity attributable to shareholders increased to ¥1,218,712,834.06 in Q1 2022, up from ¥1,161,260,410.29 in Q1 2021, indicating strong financial health[15] - Total comprehensive income for the current period is 57,452,423.77, compared to 34,217,953.38 in the previous period, indicating a strong performance[19] Cash Flow - The net cash flow from operating activities reached ¥82,949,425.82, marking a 48.50% increase from the previous year[4] - Cash inflow from operating activities for Q1 2022 is 371,792,629.73, compared to 264,429,445.76 in Q1 2021, reflecting a growth of approximately 40.5%[21] - The net cash flow from operating activities is 82,949,425.82, an increase from 55,859,650.78 in the previous year, showing a growth of about 48.5%[21] - Cash inflow from investment activities is 277,720,614.85, down from 383,206,534.94 in the previous year, indicating a decrease of approximately 27.6%[22] - The net cash flow from investment activities is 125,045,262.34, significantly up from 35,300,985.32 in the previous year, marking an increase of over 254%[22] - The net increase in cash and cash equivalents for the current period is 206,281,746.86, compared to 90,300,212.08 in the previous period, representing a growth of approximately 128.5%[22] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,491,411,760.77, a 4.72% increase from the end of the previous year[5] - The company's total assets increased to ¥1,491,411,760.77 in Q1 2022, up from ¥1,424,174,930.07 in Q1 2021, reflecting a growth of 4.7%[15] - Current liabilities amounted to ¥187,820,312.35 in Q1 2022, an increase of 5.0% from ¥177,227,273.41 in Q1 2021[15] Research and Development - R&D investment totaled ¥40,936,298.58, which is 11.87% of operating revenue, a decrease of 2.96 percentage points year-on-year[5] - Research and development expenses for Q1 2022 were ¥20,347,219.38, up from ¥17,184,346.04 in Q1 2021, indicating a focus on innovation[17] Shareholder Information - The number of shares held by the top shareholder, Yang Ying, is 138,077,266, representing 33.94% of the total shares[10] - The second-largest shareholder, Tonghua Dongbao Pharmaceutical Co., Ltd., holds 85,700,114 shares, accounting for 21.07%[10] - The company has no reported related party transactions among the top ten shareholders[11] - The company has a total of 4,000,000 shares held under a collective asset management plan, indicating active participation in strategic investments[11] Inventory and Current Assets - The total current assets reached RMB 856.92 million, compared to RMB 834.42 million at the end of 2021, indicating a slight increase of 2.1%[13] - The company's inventory stood at RMB 118.47 million, showing a marginal increase from RMB 116.49 million in the previous year[13] - The company’s accounts receivable decreased to RMB 183.03 million from RMB 186.37 million, reflecting a decline of 1.8%[13] Community Commitment - The company made cash donations totaling RMB 2.63 million during the reporting period, as part of its commitment to public welfare projects[12] - The company has committed to donate a total of RMB 20 million to the China Hepatitis Prevention Foundation over a period ending June 30, 2027, with an additional RMB 17.74 million pledged in January 2022[12] Market Performance - The company experienced a significant increase in sales revenue due to improved market penetration of its products, particularly in hepatitis B treatment[8] - The overall expense ratio has decreased, contributing to the increase in profit alongside revenue growth[8] - The company reported a significant increase in sales expenses, which reached ¥173,460,312.73 in Q1 2022, compared to ¥108,808,481.49 in Q1 2021, reflecting aggressive market expansion efforts[17] Strategic Focus - The company has made significant investments in new technologies and products, although specific figures were not disclosed in the report[20] - The company has not reported any net profit from the merged entity prior to the merger, maintaining a focus on organic growth[20]

Financial Performance - The company's revenue for 2021 was CNY 1,132,227,709.90, representing a 42.61% increase compared to CNY 793,934,304.42 in 2020[16]. - Net profit attributable to shareholders for 2021 was CNY 181,200,959.24, a 55.44% increase from CNY 116,569,580.68 in 2020[16]. - The net cash flow from operating activities for 2021 was CNY 234,781,023.63, showing a significant increase of 153.52% compared to CNY 92,608,250.58 in 2020[16]. - The company's total assets at the end of 2021 were CNY 1,424,174,930.07, a 19.40% increase from CNY 1,192,733,961.09 at the end of 2020[16]. - Basic earnings per share for 2021 were CNY 0.45, up 55.17% from CNY 0.29 in 2020[17]. - The net profit after deducting non-recurring gains and losses for 2021 was CNY 196,401,723.00, a 77.36% increase from CNY 110,737,455.86 in 2020[16]. - The company's net assets attributable to shareholders at the end of 2021 were CNY 1,161,260,410.29, a 16.08% increase from CNY 1,000,399,451.05 at the end of 2020[16]. - The company's operating revenue for the reporting period increased by 42.61% year-on-year, primarily due to the rising market penetration of its product, Pegbivac, as awareness of chronic hepatitis B clinical cure evidence grows[18]. - The net profit attributable to shareholders increased by 55.44% year-on-year, driven by revenue growth and a decrease in overall expense ratio[18]. - The net cash flow from operating activities increased by 153.52% year-on-year, attributed to timely collection of receivables and increased cash from sales of goods and services[18]. Research and Development - The company's R&D expenditure as a percentage of revenue was 14.76% in 2021, a decrease of 1.80 percentage points from 16.56% in 2020[17]. - The total R&D investment for the year was approximately ¥167.12 million, an increase of 27.09% compared to the previous year[45]. - The company applied for 98 new patents during the year, of which 42 were granted, bringing the total granted patents to 140[44]. - The company has initiated several new drug development projects, including YPEG-GH and YPEG-G-CSF, with ongoing clinical trials at various phases[29]. - The company is focusing on the clinical research of three long-acting protein new drugs and several candidate innovative drugs, indicating a robust pipeline[56]. - The company has established a complete R&D system covering upstream and downstream technology development, quality research, and clinical studies, enhancing its core competitiveness[35]. - The company has developed advanced core technologies in drug screening, PEGylation modification, and protein drug production, ensuring sustainable innovation and industrialization capabilities[41]. - The company has established a drug screening and optimization platform that allows for high-throughput screening of GPCR-targeted drugs, enhancing the efficiency of drug development[41]. Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development to drive future growth[10]. - The company is actively exploring tumor immunotherapy, with its product Granulocyte-Macrophage Colony-Stimulating Factor showing promising clinical research results presented at major conferences[27]. - The company has established a nationwide marketing network covering over 1,000 secondary and tertiary medical institutions, enhancing product recognition among doctors and patients[92]. - The company is committed to supporting the "Healthy China" strategy through its research and development efforts in oncology and hepatitis treatment[28]. - The company is focusing on the clinical cure for chronic hepatitis B while advancing multiple ongoing clinical research projects[32]. - The company aims to enhance new drug innovation and application, increasing investment in R&D and accelerating the clinical development and industrialization of new drugs[123]. Corporate Governance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[3]. - The board of directors has confirmed that all members attended the board meeting[3]. - The company has not reported any instances of more than half of the directors being unable to guarantee the authenticity, accuracy, and completeness of the annual report[5]. - The company has established a clear cash dividend policy, prioritizing cash dividends over stock dividends, especially in the absence of significant investment plans[159]. - The company completed the election of a new board of directors and supervisory board, appointing new senior management personnel during the reporting period[135]. - The company has not been subject to penalties from securities regulatory authorities in the past three years[142]. - The company has implemented a comprehensive internal control system, with no significant deficiencies reported in financial or non-financial reporting[163]. Social Responsibility and Environmental Initiatives - The company actively participates in social responsibility initiatives, supporting various public welfare projects related to hepatitis treatment since 2018[169]. - The company donated 1 million yuan to support disaster relief efforts during extreme rainfall in Henan province[170]. - The company has established an Environmental, Health, and Safety (EHS) project department to oversee environmental protection efforts and plans to utilize idle rooftop space for photovoltaic power generation[168]. - The company has implemented a resource management program to optimize energy consumption and reduce waste, focusing on electricity, water, and industrial steam[175]. - The company has been recognized as an environmentally trustworthy enterprise in Xiamen's environmental credit evaluation[178]. - The company has implemented upgrades to its wastewater treatment system, enhancing pollutant processing capabilities and ensuring compliance with discharge standards[180]. Risks and Challenges - Risks include potential failure in drug development and challenges in converting R&D results into marketable products, which could impact returns on investment[57]. - The company faces risks related to drug bidding failures and price reductions, which could affect sales revenue and net profit[58]. - The company is exposed to financial risks, including potential increases in bad debts as sales scale up[60]. - The ongoing COVID-19 pandemic has impacted hospital operations and patient treatment, which may affect clinical trial progress[62]. - The domestic pharmaceutical industry is undergoing significant reforms, with a focus on cost control and price reduction, impacting the competitive landscape[121].

Financial Performance - The company's revenue for Q3 2021 reached ¥340,550,329.12, representing a year-over-year increase of 69.46%[4] - Net profit attributable to shareholders for Q3 2021 was ¥55,583,634.62, an increase of 87.46% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥67,382,545.10, reflecting a significant increase of 121.59% year-over-year[4] - Total revenue for the first three quarters of 2021 reached ¥809,788,878.19, a significant increase of 44.4% compared to ¥560,521,811.85 in the same period of 2020[19] - The net profit for the current period is 127,688,290.01 RMB, representing an increase of 67.5% compared to 76,262,628.71 RMB in the previous period[20] - The total profit for the current period is 164,938,702.91 RMB, up from 89,561,251.71 RMB, indicating an increase of 84.3%[20] - Operating profit has risen to 191,556,085.91 RMB, compared to 103,989,914.26 RMB, reflecting a growth of 84.0%[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,346,988,287.75, a 12.93% increase from the end of the previous year[5] - The company's total assets as of Q3 2021 amounted to ¥1,346,988,287.75, compared to ¥1,192,733,961.09 in Q3 2020, representing an increase of 12.9%[18] - The total liabilities for Q3 2021 were ¥239,240,546.69, up from ¥192,334,510.04 in Q3 2020, indicating a rise of 24.4%[17] - The total liabilities amounted to $192.33 million, an increase from $204.72 million in the previous period[28] - Total equity attributable to shareholders reached ¥1,000,399,451.05, indicating a stable financial position[30] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥174,952,932.27, reflecting a year-over-year increase of 191.72%[5] - Cash flow from operating activities generated a net amount of 174,952,932.27 RMB, significantly higher than 59,972,038.67 RMB from the previous period, marking an increase of 191.5%[24] - Cash inflow from investment activities totaled 684,118,316.80 RMB, compared to 603,543,041.26 RMB, showing an increase of 13.4%[24] - The total cash and cash equivalents at the end of the period amounted to $310.42 million, up from $287.62 million previously[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,371, with the top ten shareholders holding a combined 85.85% of shares[10] - Yang Ying, the largest shareholder, holds 138,077,266 shares, representing 33.94% of total shares[10] - The second largest shareholder, Tonghua Dongbao Pharmaceutical Co., Ltd., holds 114,185,114 shares, accounting for 28.07%[10] - The company has no pledged, marked, or frozen shares among the top ten shareholders[10] Research and Development - Research and development expenses totaled ¥38,873,996.54, accounting for 11.42% of revenue, a decrease of 7.36 percentage points compared to the previous year[5] - Research and development expenses increased to ¥56,853,312.07 in 2021 from ¥44,868,117.76 in 2020, marking a growth of 26.7%[19] Donations and Social Responsibility - The company completed cash donations of 5.25 million RMB for the "China Chronic Hepatitis B Clinical Cure (Everest) Project" during the reporting period[13] - The company has donated a total of 250,000 doses of Peginterferon during the project period, fulfilling its donation obligations[13] - The company plans to donate a total of 20 million RMB to the "China Reducing Hepatitis B Patients' Liver Cancer Incidence Research (Oasis) Project" over six years, with 650,000 RMB donated as of September 30, 2021[13] - The company has completed the donation of 116,300 doses of Peginterferon under the Beijing Red Heart Communication Public Welfare Foundation agreement[13] Financial Adjustments and Standards - The company adopted new leasing standards effective January 1, 2021, impacting financial statement adjustments[30] - The company has not reported any audit opinions applicable for the financial statements as of September 30, 2021[14]

Financial Performance - The company reported a total revenue of RMB 200 million for the first half of 2021, representing a year-on-year increase of 15%[2]. - The net profit attributable to shareholders was RMB 50 million, with a profit margin of 25%[2]. - The company's operating revenue for the first half of 2021 was ¥469,238,549.07, representing a 30.50% increase compared to ¥359,557,571.99 in the same period last year[15]. - Net profit attributable to shareholders for the same period was ¥72,104,655.39, up 54.69% from ¥46,611,804.16 in the previous year[15]. - The net cash flow from operating activities surged by 246.11%, amounting to ¥100,731,036.69, compared to ¥29,103,857.99 in the previous year[15]. - Basic earnings per share rose by 50% to ¥0.18 from ¥0.12 in the same period last year[16]. - The company has set a revenue guidance of RMB 450 million for the full year 2021, indicating a growth target of 20% compared to 2020[2]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 25% year-over-year growth[109]. - The company achieved operating revenue of 46,923.85 million RMB, a year-on-year increase of 30.50%[52]. - Net profit attributable to shareholders reached 7,210.47 million RMB, reflecting a growth of 54.69% compared to the previous year[52]. User Growth and Market Expansion - User data indicated a growth in active users by 20%, reaching a total of 1 million active users by the end of June 2021[2]. - The company plans to launch two new products in Q3 2021, aiming to capture an additional 10% market share in the next year[2]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a revenue contribution of 5% from this region by the end of 2022[2]. - The company is actively exploring new business models and enhancing its talent incentive policies to mitigate potential risks[49]. - Market expansion plans include entering three new international markets by Q3 2021, projected to increase user base by 30%[88]. Research and Development - Research and development expenses increased by 30%, totaling RMB 30 million, reflecting the company's commitment to innovation[2]. - The company focuses on the research, development, production, and sales of recombinant proteins and long-acting modified drugs, aiming to become a leader in systemic immune solutions based on cytokine drugs[20]. - The company has launched four products: Pegb interferon, Terluz, Terlil, and Terlil, with Pegb being the world's first 40kD pegylated interferon α-2b injection, a first-line antiviral treatment for chronic hepatitis B[20]. - The company is focusing on chronic hepatitis B clinical cure strategies, which will be a significant research direction in the field of hepatitis B treatment[28]. - The company reported a total R&D investment of approximately ¥69.29 million, a 52.57% increase from the previous year, with R&D expenses accounting for 14.77% of operating revenue[33]. Strategic Initiatives and Acquisitions - A strategic acquisition of a smaller biotech firm is in progress, expected to enhance the company's product pipeline and increase market competitiveness[2]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[86]. - The company has established a strategic partnership with Suzhou Aikebaifa Biotechnology Co., Ltd. for the AK0706 project, which is currently in the preclinical research stage[36]. Compliance and Risk Management - The management highlighted potential risks related to regulatory changes that could impact product approvals and market access[2]. - The company faces risks related to industry regulations that may impact drug pricing and economic benefits[48]. - The company emphasizes compliance with all relevant laws and regulations regarding share transfers and reductions[93]. Environmental and Social Responsibility - The company emphasized its focus on sustainable practices and corporate social responsibility initiatives, aiming to reduce carbon emissions by 15% by 2025[2]. - The company has implemented measures to reduce carbon emissions, including promoting waste sorting and encouraging green office practices[72]. - The company donated 1 million yuan to support disaster relief efforts in Henan following severe flooding in July 2021[73]. Shareholder and Equity Management - The company has committed to not transferring shares for 36 months post-IPO, ensuring stability in shareholding[75]. - The company has established a framework for monitoring and maintaining environmental facilities, including wastewater treatment and emissions control[71]. - The company will ensure compliance with information disclosure obligations when reducing shareholdings[97]. Financial Health and Assets - The company's total assets at the end of the reporting period were ¥1,258,000,119.28, a 5.47% increase from ¥1,192,733,961.09 at the end of the previous year[15]. - The net assets attributable to shareholders increased by 5.17% to ¥1,052,164,106.44 from ¥1,000,399,451.05 at the end of the previous year[15]. - The company has a total of 151 R&D personnel, representing 15.35% of the total workforce, with an average salary of ¥10.76 million[37]. Governance and Compliance - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board[171]. - The company adheres to the accounting standards for enterprises, ensuring the financial statements reflect a true and complete picture of its financial status[176]. - The company prepares consolidated financial statements reflecting the overall financial position, operating results, and cash flows of the entire corporate group[179].

Financial Performance - The company's operating revenue for 2020 was approximately ¥793.93 million, representing an 8.81% increase from ¥729.67 million in 2019[16]. - The net profit attributable to shareholders for 2020 was approximately ¥116.57 million, an increase of 81.31% compared to ¥64.29 million in 2019[16]. - The net profit after deducting non-recurring gains and losses was approximately ¥110.74 million, which is a 28.11% increase from ¥86.44 million in 2019[16]. - The company's total assets at the end of 2020 were approximately ¥1.19 billion, a 51.01% increase from ¥789.83 million at the end of 2019[16]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥1.00 billion, reflecting a 77.52% increase from ¥563.55 million at the end of 2019[16]. - The basic earnings per share for 2020 was ¥0.29, a 61.11% increase from ¥0.18 in 2019[17]. - The company's net cash flow from operating activities in Q4 2020 was ¥32,636,211.91, indicating strong cash generation capabilities[19]. - The company reported non-recurring gains of ¥26,633,900.81 in 2020, significantly higher than ¥15,470,490.54 in 2019[20]. - The company achieved operating revenue of RMB 793,934,304.42, representing a year-on-year growth of 8.81%[67]. - Net profit attributable to shareholders reached RMB 116,569,600, marking a significant increase of 81.31% year-on-year[66]. - The net assets attributable to shareholders grew to RMB 1,000,399,500, reflecting a year-on-year increase of 77.52%[66]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 16.56% in 2020, up from 8.87% in 2019, indicating a significant focus on innovation[17]. - The total R&D investment for the year reached ¥131,496,033.12, a significant increase of 103.09% compared to ¥64,748,523.67 in the previous year, with R&D expenses accounting for 16.56% of operating income, up by 7.69 percentage points[39]. - The company is focusing on the prevention and treatment of chronic hepatitis B and its complications, such as liver cancer and cirrhosis, as key research directions for the future[33]. - The company is conducting Phase III clinical trials for its long-acting interferon targeting hepatitis B surface antigen clearance, which is a key efficacy indicator for chronic hepatitis B clinical cure research[36]. - The company has developed five long-acting PEGylated protein drugs approved for clinical research, including Peginterferon α-2b, which was launched in 2016 and is the first long-acting interferon product with independent intellectual property rights in China[33]. - The company has established a unique and mature core capability for long-acting drug modification, suitable for industrial-scale production with excellent cost control characteristics[34]. - The company has invested a total of ¥579 million in R&D projects, with ¥131.5 million invested in the current period and a cumulative investment of ¥276.9 million[43]. - The company is actively involved in clinical research for chronic hepatitis B treatment, aiming to enhance clinical cure rates and reduce liver cancer risks for patients[32]. - The company has several ongoing projects, including YPEG-GH and YPEG-GCSF, both in advanced clinical research stages, indicating a robust pipeline[100]. Market Position and Strategy - The company aims to expand its product sales, particularly in chronic hepatitis B treatment, leveraging accumulated clinical evidence[17]. - The company is recognized as a leading enterprise in the field of polyethylene glycol protein long-acting drugs in China, with a focus on major disease treatment and a robust innovation platform[31]. - The company has launched four products, including Peginterferon α-2b injection, which is a first-line treatment for chronic hepatitis B[23]. - The company is positioned to leverage its first-mover advantage in the chronic hepatitis B treatment market with Pegbinterferon[117]. - The company is focusing on innovation and R&D to enhance its market position amid increasing competition and regulatory scrutiny in the pharmaceutical industry[90]. - The company has a specialized marketing team and has expanded its academic promotion network across the country to enhance its market presence in oncology and viral hepatitis[52]. - The company is actively exploring treatment strategies for special populations, including children with chronic hepatitis B, to improve overall clinical cure rates[53]. - The company has established a strategic partnership with Suzhou Aikebaifa Biopharmaceutical Technology Co., Ltd. for the AK0706 project, which is currently in the preclinical research stage[44]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[3]. - The board of directors and senior management confirm the authenticity, accuracy, and completeness of the annual report[2]. - The company has not proposed any capital reserve transfer to increase share capital or bonus shares for the 2020 profit distribution plan[4]. - The company has not disclosed any special arrangements for corporate governance[4]. - The company has established a clear plan to maintain shareholder confidence and regulatory compliance[142]. - The company has a proactive approach to managing shareholder relations and regulatory compliance[144]. - The company has a strict adherence to legal obligations, with no violations reported in the last six months[144]. - The company has committed to maintaining a cash dividend distribution of at least 40% if it is in a mature stage with significant capital expenditure plans[124]. Risks and Challenges - The company faces risks related to the inability to convert R&D results into marketable products, which could significantly affect the return on prior investments[59]. - The company is exposed to risks from potential failures in drug bidding processes, which could lead to declines in sales revenue and net profit[60]. - The company acknowledges the competitive landscape for talent in the biopharmaceutical industry, which could impact its long-term development if not managed effectively[63]. - The company is subject to macroeconomic risks, particularly from government policies that may enforce drug price reductions, directly affecting economic performance[64]. - The company is aware of the challenges posed by its expanding operational scale, necessitating adjustments in internal controls and management systems to support rapid growth[65]. Shareholder Commitments and Regulations - The company has committed to not transferring or entrusting the management of shares held prior to the IPO for 36 months from the date of listing[130]. - The company has established a commitment to not reduce shares during specific legal and regulatory investigations or penalties[136]. - The company has a strict adherence to the lock-up period, with commitments from major shareholders to not sell shares for two years after the lock-up period ends[149]. - The company will ensure compliance with all relevant laws and regulations regarding share reduction and commitments[136]. - The company has outlined specific penalties for non-compliance with share sale commitments, ensuring accountability[150]. Financial Management - The company has a total of ¥190,000,000 in fixed deposits from raised funds, with no overdue amounts[177]. - The company has invested ¥446,000,000 in structured deposits from raised funds, with an annualized return rate of 3.10%[178]. - The total amount of entrusted financial management reached ¥1,200,000,000, with a balance of ¥105,000,000 remaining[177]. - The company has achieved a return of ¥720,273.96 from a bank financial product with an annualized return rate of 2.26%[179]. - The company has a total of ¥50,000,000 in seven-day notice deposits with an annualized return rate of 1.89%[179]. Environmental and Social Responsibility - The company has successfully maintained compliance with environmental regulations, ensuring that all pollutants are within the required standards[195]. - The company has undergone ISO 14001:2015 environmental management system certification, valid from May 14, 2020, to May 13, 2023[196]. - During the pandemic, the company donated nearly 400,000 yuan worth of medical protective supplies to support frontline efforts[194].

Financial Performance - Net profit attributable to shareholders increased by 81.21% to CNY 76,262,628.71 year-on-year[5] - Operating income rose by 6.14% to CNY 560,521,811.85 for the first nine months of the year[5] - Basic earnings per share increased by 58.33% to CNY 0.19[5] - The weighted average return on equity increased by 0.47 percentage points to 8.56%[5] - The company reported a significant increase in retained earnings, reaching CNY 153,074,712.92, up from CNY 95,110,401.53 year-over-year[21] - Net profit for Q3 2020 reached CNY 29,650,824.55, an increase of 8.0% from CNY 26,537,411.47 in Q3 2019[24] - Net profit for Q3 2020 increased to CNY 26,993,177.91, up 13.5% from CNY 23,875,643.71 in Q3 2019[27] Assets and Liabilities - Total assets increased by 43.04% to CNY 1,129,746,093.83 compared to the end of the previous year[5] - Total liabilities decreased to CNY 189,386,553.33 from CNY 258,193,494.13 year-over-year, indicating a reduction of approximately 26.7%[21] - Total current assets increased to ¥737,394,694.41 from ¥445,199,859.52, representing a growth of approximately 65.6% year-over-year[17] - Total liabilities decreased to ¥169,653,594.75 from ¥226,271,510.62, a reduction of about 25%[19] - The company's equity attributable to shareholders increased to ¥960,092,499.08 from ¥563,553,550.37, reflecting a growth of approximately 70.4%[19] Cash Flow - Net cash flow from operating activities decreased by 9.13% to CNY 59,972,038.67 year-to-date[5] - Cash flow from operating activities for the first nine months of 2020 was CNY 559,981,356.35, an increase from CNY 542,510,600.01 in the same period of 2019[29] - The company reported a net cash flow from operating activities of CNY 57,081,142.10 for the first nine months of 2020, down from CNY 62,215,742.49 in the same period last year, indicating a decrease of about 8.5%[32] - Total cash and cash equivalents at the end of Q3 2020 reached CNY 287,621,977.44, up from CNY 164,716,295.08 at the end of Q3 2019, representing a growth of approximately 74.5%[31] Research and Development - R&D expenditure accounted for 14.83% of operating income, an increase of 6.43 percentage points compared to the previous year[5] - Development expenditures surged by 171.18% to RMB 60,643,601.62, reflecting ongoing investments in clinical research[11] - Research and development expenses for Q3 2020 were CNY 11,200,776.60, slightly down from CNY 11,585,727.78 in Q3 2019[23] - R&D expenses for Q3 2020 were CNY 9,984,530.11, slightly down from CNY 10,375,318.42 in Q3 2019[27] Government Support and Subsidies - Government subsidies recognized in the current period amounted to CNY 1,754,170.43[6] - Other income increased by 198.04% to RMB 18,245,218.33, driven by IPO subsidies and other government grants[12] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,222[8] - The company completed the renewal of its Drug Production License, valid until September 22, 2025[14] Investment and Financing Activities - Net cash outflow from investing activities was CNY -259,013,012.64, compared to CNY -29,704,224.79 in the same period last year, indicating a significant increase in investment expenditures[30] - Net cash flow from financing activities was CNY 281,113,759.74, a turnaround from a net outflow of CNY -16,906,662.48 in Q3 2019, showing improved financing conditions[31]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2020, representing a year-on-year increase of 20%[13]. - The net profit attributable to shareholders for the same period was RMB 30 million, up 15% compared to the previous year[13]. - The company's operating revenue for the first half of 2020 was approximately ¥359.56 million, representing a year-on-year increase of 12.83%[20]. - The net profit attributable to shareholders for the same period was approximately ¥46.61 million, a significant increase of 199.81% compared to the previous year[20]. - The company achieved a revenue of RMB 359.56 million in the first half of 2020, representing a year-on-year growth of 12.83%[55]. - The net profit attributable to shareholders reached RMB 46.61 million, showing a significant increase of 199.81% year-on-year[55]. - The company reported a significant increase in revenue for the first half of 2020, with a year-over-year growth of 15%[96]. - The company reported a total profit of RMB 48,666,229.39 for the first half of 2020, compared to RMB 15,125,572.10 in the same period of 2019, marking an increase of 221.5%[175]. User Growth and Market Expansion - User data indicated a growth in active users by 25%, reaching a total of 500,000 users by the end of June 2020[13]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2021[13]. - User data showed an increase in active users to 10 million, up from 8 million in the previous period, marking a growth of 25%[88]. - Market expansion plans include entering three new international markets by Q3 2020, which is expected to increase market share by 15%[89]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of 100 million allocated for potential deals[87]. Research and Development - New product development includes the launch of a PEGylated interferon product, expected to enter clinical trials in Q4 2020[13]. - Research and development expenses increased by 10%, totaling RMB 15 million, reflecting the company's commitment to innovation[13]. - The company has developed a complete innovative drug R&D system, focusing on upstream and downstream technology development, quality research, and clinical studies[30]. - The core technology includes a PEGylation platform that enhances the stability and efficacy of protein drugs, with a patented Y-shaped PEG structure that improves drug characteristics[34][35]. - The company has achieved international patent authorization for its core technologies in Europe, the United States, and Japan, indicating its advanced technological position[36]. - The company is advancing 6 key R&D projects, including YPEG-GH and YPEG-G-CSF, which are in phase III clinical trials[57]. - R&D investment increased by 59.69% year-on-year, totaling approximately ¥45.42 million, which represents 12.63% of the company's revenue[38]. Financial Guidance and Future Outlook - The company has set a performance guidance for the second half of 2020, aiming for a revenue growth of 25%[13]. - The company provided guidance for the next quarter, expecting revenue to reach between 1.6 billion and 1.7 billion, indicating a potential growth of 7% to 13%[89]. - The company plans to strengthen its market position by continuously monitoring industry competition and advancing new technology development[63]. Risk Management and Compliance - The board has highlighted potential risks related to regulatory changes in the biopharmaceutical industry[4]. - The company is focusing on risk management and team building to improve overall management levels and enhance risk prevention capabilities[60]. - The company is facing potential risks related to industry policies, R&D challenges, and market competition that could impact future performance[61]. Shareholder Commitments and Governance - The company committed to not transferring or entrusting the management of shares held prior to the IPO for 36 months from the date of listing[84]. - The company will not reduce shares if it is under investigation for securities violations or has been publicly reprimanded by the stock exchange[86]. - The company will ensure that any share reduction after the lock-up period does not affect its operational stability and will disclose control arrangements[83]. - The company will bear legal responsibilities for any failure to fulfill its commitments regarding share transfers[83]. Environmental and Compliance Standards - Environmental protection facilities operated normally during the reporting period, with all pollutants meeting discharge standards[127]. - The company achieved compliance with environmental monitoring requirements, with third-party testing confirming adherence to national standards[128]. - The company received ISO 14001:2015 environmental management system re-certification in May 2020[128]. Financial Management and Cash Flow - The net cash flow from operating activities was approximately ¥29.10 million, showing a decrease of 6.33% year-on-year[20]. - Cash and cash equivalents at the end of the period reached ¥361,918,070.55, accounting for 31.98% of total assets, a 130.27% increase compared to the same period last year[69]. - The company has engaged in cash management strategies to enhance fund utilization efficiency while ensuring operational needs and fund safety[135].

Financial Performance - Net profit attributable to shareholders increased by 4,024.37% to CNY 22,359,658.11 compared to the same period last year[4]. - Operating income rose by 28.02% to CNY 187,502,306.06 compared to the same period last year[4]. - Basic earnings per share increased by 2,900% to CNY 0.06 compared to the same period last year[4]. - Net profit increased by 31.06% to ¥94,354,124.08, reflecting continuous growth in retained earnings[12]. - The company reported a significant increase in other income, which rose by 488.65% to ¥11,707,227.90, mainly due to increased government subsidies[12]. - Total operating revenue for Q1 2020 was ¥187,502,306.06, an increase of 27.9% compared to ¥146,459,314.47 in Q1 2019[24]. - Net profit for Q1 2020 reached ¥22,359,658.11, compared to ¥542,134.56 in Q1 2019, indicating a significant increase[25]. - The total comprehensive income for Q1 2020 was ¥22,359,658.11, compared to ¥542,134.56 in Q1 2019, indicating strong performance[26]. - The net profit for Q1 2020 was ¥19,325,820.31, a significant increase compared to a net loss of ¥920,805.65 in Q1 2019, representing a turnaround in profitability[28]. Assets and Liabilities - Total assets increased by 43.63% to CNY 1,134,452,277.91 compared to the end of the previous year[4]. - The company's cash and cash equivalents increased by 92.10% to ¥395,510,817.60, primarily due to the proceeds from the initial public offering[11]. - Total current liabilities decreased to CNY 142,111,698.84 from CNY 150,724,824.88, reflecting a reduction of about 5.4%[20]. - The total liabilities decreased to CNY 218,092,749.43 from CNY 226,271,510.62, indicating a reduction of approximately 3.6%[21]. - The company's equity attributable to shareholders increased to CNY 916,359,528.48, up from CNY 563,553,550.37, which is an increase of approximately 62.7%[21]. - The total cash and cash equivalents at the end of Q1 2020 reached ¥395,510,817.60, compared to ¥157,886,560.69 at the end of Q1 2019, showing a significant increase of approximately 150%[30]. - The total liabilities as of Q1 2020 were ¥254,755,785.01, a slight decrease from ¥258,193,494.13 in the previous year[23]. Cash Flow - The net cash flow from operating activities decreased by 27.73% to CNY 13,032,237.07 compared to the same period last year[4]. - The company reported a net cash inflow from financing activities of ¥335,961,607.50, primarily from the initial public offering[13]. - The net cash inflow from financing activities was CNY 335,961,607.50, compared to a net outflow of CNY 875,437.49 in the previous period[32]. - Cash inflow from operating activities totaled ¥210,955,637.24 in Q1 2020, compared to ¥172,702,303.03 in Q1 2019, marking an increase of approximately 22.1%[29]. - The net cash flow from financing activities in Q1 2020 was ¥335,961,607.50, a notable improvement compared to a negative cash flow of ¥875,437.49 in Q1 2019[30]. Research and Development - The proportion of R&D investment to operating income increased by 0.93 percentage points to 10.67%[4]. - Research and development expenses for Q1 2020 were ¥15,376,305.90, up from ¥14,171,427.94 in Q1 2019, reflecting a 8.5% increase[24]. Shareholder Information - The company had a total of 10,833 shareholders at the end of the reporting period[7]. - The top shareholder, Yang Ying, holds 33.94% of the shares, totaling 138,077,266 shares[7]. Investment Activities - The company has utilized a maximum of ¥220 million of idle raised funds for cash management, with a one-year authorization period[15]. - The company has invested ¥130 million in structured deposits and ¥50 million in bank financial products, achieving annualized returns of 3.26% and 2.05-2.65% respectively[14]. - The company reported a credit impairment loss of ¥639,345.17 in Q1 2020, compared to a gain of ¥345,963.07 in Q1 2019[24]. - The company recovered ¥180,000,000.00 from investments in Q1 2020, consistent with the previous year, indicating stable investment recovery[31]. Donations and Social Responsibility - The company completed cash donations of ¥4.5 million as part of its commitment to the "China Hepatitis B Clinical Cure (Everest) Project" during the reporting period[16]. - The company has a plan to donate a total of 25,000 vials of Peginterferon, with 20,000 vials already donated by the end of the reporting period[16].